SAN FRANCISCO, Sept. 3, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at upcoming investor conferences:
- H.C. Wainwright 26th Annual Global Investment Conference in New York City on Monday, September 9, 2024 at 3:00 p.m. Eastern Time / 12:00 p.m. Pacific Time
- Stifel Virtual Immunology and Inflammation Summit on Tuesday, September 17, 2024 at 12:30 p.m. Eastern Time / 9:30 a.m. Pacific Time
The presentations will be accessible via webcast through links posted on the Investor Events section of the Nektar website: . The webcasts will be available for replay until October 9, 2024 and October 17, 2024, respectively.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Our pipeline also includes a preclinical candidate NKTR-0165, which is a bivalent tumor necrosis factor receptor type II agonist antibody. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in San Francisco, California. For further information, visit and follow us on LinkedIn.
Contact:
For Investors:
Vivian Wu of Nektar Therapeutics
628-895-0661
For Media:
David Rosen of Argot Partners
(212) 600-1902
david.rosen@argotpartners.com
View original content to download multimedia:
SOURCE Nektar Therapeutics
舊金山,2024年9月3日 /PRNewswire/ — Nektar Therapeutics(納斯達克股票代碼:NKTR)管理層計劃在即將舉行的投資者會議上發表演講:
- H.C. Wainwright 第 26 屆年度全球投資會議將於 2024 年 9 月 9 日星期一美國東部時間下午 3:00 /太平洋時間下午 12:00 在紐約市舉行
- Stifel 虛擬免疫學和炎症峯會將於 2024 年 9 月 17 日星期二美國東部時間下午 12:30 /太平洋時間上午 9:30
可以通過Nektar網站 「投資者活動」 部分上發佈的鏈接通過網絡直播觀看演示文稿:.網絡直播將分別在2024年10月9日和2024年10月17日之前重播。
關於 Nektar Therapeu
Nektar Therapeutics是一家處於臨床階段的生物技術公司,專注於開發治療自身免疫和慢性炎症性疾病中潛在免疫功能障礙的治療方法。Nektar的主要候選產品rezpegaldesleukin(NKTR-358)是一種新型、同類首創的調節性T細胞刺激劑,正在兩項20期臨床試驗中進行評估,一項針對特應性皮炎,另一項用於脫髮。我們的產品線還包括臨床前候選藥物 NKTR-0165,這是一種二價腫瘤壞死因子受體 II 型激動劑抗體。Nektar 還與多家合作伙伴一起在多項正在進行的臨床試驗中評估 NKTR-255,這是一種在研的 IL-15 受體激動劑,旨在增強免疫系統對抗癌症的自然能力。Nektar 總部位於加利福尼亞州舊金山。欲了解更多信息,請訪問並在 LinkedIn 上關注我們。
聯繫人:
對於投資者:
Nektar Therapeutics 的吳薇安
628-895-0661
對於媒體:
Argot Partners 的大衛羅森
(212) 600-1902
david.rosen@argotpartners.com
查看原創內容以下載多媒體:
來源 Nektar Therapeut